DDrare: Database of Drug Development for Rare Diseases

Searched query = "Huntington disease", "Huntington chorea"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = (2)-epigallocatechin-3-gallate (EGCG); 20 mg BID of PF-02545920; 20mg daily citalopram; 5-Chloro-1,2-dihydro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-3-quinolinecarboxamide sodium; ACR16; ACR16 10 mg; ACR16 22.5 mg; ACR16 45 mg; ACR16 hydrochloride, ASP2314 hydrochloride, FR310826; AFQ056; ANX005; Alprazolam; Amantadine; Anti-Parkinson medication; Atomoxetine; Autologous Stem Cell; BEVANTOLOL HYDROCHLORIDE; BN82451B; BN8251B; Bevantolol; Biotin; Blood sample; Bupropion; CBD; CKD-504; CYSTAGON; Calvan® 100 mg; Cannabidiol; Cellavita HD Higher dose; Cellavita HD Lower Dose; Cellavita HD higher dose; Cellavita HD lower dose; Cellavita-HD; Citalopram; CoQ10; Coenzyme Q10; Creatine; Creatine Monohydrate; Creatine monohydrate; Cystagon; Cysteamine; Cysteamine Bitartrate; DM; Delta-9-tetrahydrocannabinol; Delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD); Deutetrabenazine; Deutetrabenazine Oral Tablet [Austedo]; Device: BioStamp nPoint device; Device: Deep Brain Stimulation; Dextromethorphan; Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg); Digoxin; Dimebon; Dimebon (latrepirdine); Dimebon + Dextromethorphan; Dimebon + Ketoconazole; Dimebon + Omeprazole; Dimebon Dihydrochloride; Dimebon IR; Dimebon IR Tablet; Dimebon MR1; Dimebon MR2; Dimebon MR3; Dimebon MR4; Dimebon Transdermal; Dimebon alone; Dimebon dihydrochloride; Divalproex; EGCG; EPA; Epigallocatechin; Ethyl Icosapent; Ethyl-EPA; Ethyl-EPA (Miraxion™); Ethyl-Icosapent; Fenofibrate; GSK356278; Graft intracerebral of foetal neurons; HYPERIUM; Haloperidol; High doses of Thiamine y Biotin; Hyperium; ISIS 443139 10 mg; ISIS 443139 120 mg; ISIS 443139 30 mg; ISIS 443139 60 mg; ISIS 443139 90 mg; Icosapent; Ketoconazole; LAQUINIMOD; LAX-101; Laquinimod; Laquinimod capsules 0.5 mg; Latrepirdine; Lithium; Melatonin; Memantine; Minocycline; Moderate doses of Thiamine y Biotin; N.a.; Neflamapimod; Nilotinib; Nilotinib 150 MG; OMS643762; OSU6162 similar to (-)-OSU 6162; Olanzapine; Omeprazole; Other: 31-Phosphorus RMN Spectroscopy; PBF-999; PBF-999 / 160 mg; PBF-999 / 320 mg; PBT2; PF-02545920; PL101; PRIDOPIDINE HYDROCHLORIDE; Phenylbutyrate; Phosphorus; Pridiopidine; Pridopidina; Pridopidine; Pridopidine (90 mg); Quinidine; RG6042, formerly ISIS 443139, IONIS-HTTRx; RO7234292; RO7234292 (RG6042); RP 103; RP103; Ramelteon; Resveratrol; Rilmenidine; Riluzole; Risperidone; Ro 723-4292/F02; Rolipram; SAGE-718; SBT-020; SD-809; SEN0014196; SEN0014196 (High Dose); SEN0014196 (Low Dose); SOM3355 100mg BID; SOM3355 200mg BID; SRX246; SS-20; Selisistat; Sodium phenylbutyrate; THC; TV-5600; TV-7820; Tetrabenazine; Tetrabenazine withdrawal; Tetrahydrocannabinol; Thiamine; Tiapridal; Tominersen; Triheptanoin; Triheptanoin 1g/kg/day; Triheptanoin oil; UX007; Ubiquinol; Ursodiol; VX-745; VX15/2503; Valbenazine; WVE-120101; WVE-120102; Warfarin; Xenazine; Zoloft; [123I]MNI-420; [18F]FPEB

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ gender	Target_ size	Countries
1	EUCTR2011-001131-23-GB (EUCTR)	24/10/2011	18/07/2011	A study to determine how safe and tolerable the study drug is, when given to patients with Huntingtons Disease.	A double-blind, placebo-controlled study in Huntington’s Disease patients to determine the safety and tolerability of SEN0014196 - N/A	Huntington's disease MedDRA version: 14.1;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: SEN0014196 Product Code: SEN0014196 INN or Proposed INN: selisistat Product Name: SEN0014196 Product Code: SEN0014196 INN or Proposed INN: selisistat	Siena Biotech SpA	NULL	Not Recruiting	Female: yes Male: yes	144	Germany;Italy;United Kingdom
2	EUCTR2011-001131-23-IT (EUCTR)	20/10/2011	22/11/2011	A study to determine how safe and tolerable the study drug is, when given to patients with Huntingtons Disease.	A double-blind, placebo-controlled study in Huntington's Disease patients to determine the safety and tolerability of SEN0014196	Huntington's disease MedDRA version: 14.0;Level: SOC;Classification code 10010331;Term: Congenital, familial and genetic disorders;System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 14.0;Level: LLT;Classification code 10020469;Term: Huntington's chorea;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: SEN0014196 Product Code: SEN0014196 INN or Proposed INN: selisistat Product Name: SEN0014196 Product Code: SEN0014196 INN or Proposed INN: selisistat	SIENA BIOTECH SPA	NULL	Not Recruiting	Female: yes Male: yes	144	Germany;United Kingdom;Italy
3	EUCTR2011-001131-23-DE (EUCTR)	21/09/2011	27/06/2011	A study to determine how safe and tolerable the study drug is, when given to patients with Huntingtons Disease.	A double-blind, placebo-controlled study in Huntington’s Disease patients to determine the safety and tolerability of SEN0014196 - N/A	Huntington's disease MedDRA version: 14.1;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: SEN0014196 Product Code: SEN0014196 INN or Proposed INN: selisistat Product Name: SEN0014196 Product Code: SEN0014196 INN or Proposed INN: selisistat	Siena Biotech SpA	NULL	Not Recruiting	Female: yes Male: yes	144	Germany;Italy;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2011-001131-23-GB
(EUCTR)

24/10/2011

18/07/2011

A study to determine how safe and tolerable the study drug is, when given to patients with Huntingtons Disease.

A double-blind, placebo-controlled study in Huntington’s Disease patients to determine the safety and tolerability of SEN0014196 - N/A

Huntington's disease
MedDRA version: 14.1;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: SEN0014196
Product Code: SEN0014196
INN or Proposed INN: selisistat
Product Name: SEN0014196
Product Code: SEN0014196
INN or Proposed INN: selisistat

Siena Biotech SpA

NULL

Not Recruiting

Female: yes
Male: yes

144

Germany;Italy;United Kingdom

EUCTR2011-001131-23-IT
(EUCTR)

20/10/2011

22/11/2011

A study to determine how safe and tolerable the study drug is, when given to patients with Huntingtons Disease.

A double-blind, placebo-controlled study in Huntington's Disease patients to determine the safety and tolerability of SEN0014196

Huntington's disease
MedDRA version: 14.0;Level: SOC;Classification code 10010331;Term: Congenital, familial and genetic disorders;System Organ Class: 10010331 - Congenital, familial and genetic disorders
MedDRA version: 14.0;Level: LLT;Classification code 10020469;Term: Huntington's chorea;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Product Name: SEN0014196
Product Code: SEN0014196
INN or Proposed INN: selisistat
Product Name: SEN0014196
Product Code: SEN0014196
INN or Proposed INN: selisistat

SIENA BIOTECH SPA

NULL

Not Recruiting

Female: yes
Male: yes

144

Germany;United Kingdom;Italy

EUCTR2011-001131-23-DE
(EUCTR)

21/09/2011

27/06/2011

A study to determine how safe and tolerable the study drug is, when given to patients with Huntingtons Disease.

A double-blind, placebo-controlled study in Huntington’s Disease patients to determine the safety and tolerability of SEN0014196 - N/A

Product Name: SEN0014196
Product Code: SEN0014196
INN or Proposed INN: selisistat
Product Name: SEN0014196
Product Code: SEN0014196
INN or Proposed INN: selisistat

Siena Biotech SpA

NULL

Not Recruiting

Female: yes
Male: yes

144

Germany;Italy;United Kingdom